Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
Varuni Kondagunta
G
G
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Bacik
Jennifer
J
Schwartz
Lawrence
L
Sheinfeld
Joel
J
Bajorin
Dean
D
Vuky
Jacqueline
J
Marion
Stephanie
S
Mazumdar
Madhu
M
Bosl
George J
GJ
Motzer
Robert J
RJ
D000328:Adult; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D016001:Confidence Intervals; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000502:physiology; D005260:Female; D018237:Germinoma / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008479:Mediastinal Neoplasms / Q000097:blood / Q000188:drug therapy; D000077204:Temozolomide; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy
D003606:Dacarbazine; D002945:Cisplatin; D000077204:Temozolomide